X-GEN receives go-ahead for acetazolamide for glaucoma

Big Flats, NY

-X-GEN Pharmaceuticals Inc. will begin marketing injectable acetazolamide for indications including open-angle glaucoma and secondary glaucoma as well as preoperative use for the treatment of acute angle-closure glaucoma in cases in which surgery has been delayed to lower IOP.

The new product is equivalent to a commercially available brand (Diamox, Duramed Pharmaceuticals), according to the company. The drug is supplied as a sterile, preservative-free lyophilized powder. Each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide.

“Currently, there is only one supplier of acetazolamide for injection USP,” said Susan Badia, X-GEN president and chief executive officer. “Our launch of this product will ensure consistent supply and steady, competitive price levels.”